Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
93%
Ulcerative Colitis
72%
Clinical Remission
39%
Israeli
37%
Fecal Calprotectin
30%
Ustekinumab
28%
Vedolizumab
28%
Anti-tumor Necrosis Factor (anti-TNF)
27%
Ileal Pouch-anal Anastomosis
26%
Remission Induction
23%
Confidence Interval
23%
Disease Activity
22%
Active Ulcerative Colitis
21%
Real-world Experience
20%
Moderate to Severe
20%
Adalimumab
20%
Remission
19%
Ulcerative Colitis Patient
19%
Harvey-Bradshaw Index
17%
Clinical Response
16%
Multicenter Cohort Study
16%
Drug Levels
16%
Mucosal Healing
15%
Disease Course
14%
Non-associated
14%
COVID-19
14%
Serological Response
14%
Anti-tumor Necrosis Factor Therapy
13%
Initial Treatment
13%
Unfractionated Heparin
13%
MTHFR C677T
13%
Vitamin B12 Deficiency
13%
COVID-19 mRNA Vaccine
13%
Response to COVID-19
13%
Fecal Transplantation
13%
Complicated Disease
13%
Hazard Ratio
12%
Adverse Events
12%
Randomized Controlled Trial
11%
Pediatric Onset
11%
C-reactive Protein
10%
Homozygosity
10%
Ileal Crohn's Disease
10%
Venous Thromboembolism
10%
Odds Ratio
9%
Crohn's Colitis
9%
B12 Deficiency
9%
Maintenance Therapy
9%
Active Crohn's Disease
9%
Medicine and Dentistry
Ulcerative Colitis
94%
Crohn's Disease
68%
Inflammatory Bowel Disease
63%
Tumor Necrosis Factor
38%
Patient with Inflammatory Bowel Disease
37%
Disease Activity
31%
Faecal Calprotectin
31%
Ileo-Anal Pouch
26%
Disease
21%
Biological Product
19%
Pediatrics
19%
Disease Course
15%
Cohort Analysis
15%
Colitis
14%
Vedolizumab
14%
Elimination Diet
14%
Heparin
13%
Venous Thromboembolism
13%
Adalimumab
13%
COVID-19
13%
Fecal Microbiota Transplantation
13%
Hazard Ratio
11%
C Reactive Protein
11%
Patient with Ulcerative Colitis
10%
Randomized Controlled Trial
10%
Colectomy
9%
Infection
9%
Patient with Crohn's Disease
8%
Maintenance Therapy
8%
Colon Crohn Disease
8%
Infusion
8%
Placebo
8%
Coronavirinae
7%
Curcumin
7%
Odds Ratio
7%
Ustekinumab
7%
TNF Inhibitor
7%
Adverse Event
7%
Prospective Cohort Study
7%
Diet Therapy
7%
Personalized Medicine
6%
Autoimmune Pancreatitis
6%
Contrast-Enhanced Ultrasound
6%
Scar Formation
6%
Alopecia Mucinosa
6%
Anemia
6%
Fibrosis
6%
Case-Control Study
6%
mRNA Vaccine
6%
Scalp Psoriasis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
61%
Remission
61%
Crohn's Disease
57%
Ulcerative Colitis
50%
Tumor Necrosis Factor
36%
Vedolizumab
27%
Ustekinumab
27%
Disease Activity
23%
Cohort Study
22%
Calgranulin
21%
Adalimumab
20%
Biological Product
14%
Disease
14%
Venous Thromboembolism
13%
Heparin
13%
Adverse Event
11%
Infection
9%
Colon Crohn Disease
8%
Coronavirinae
8%
Placebo
8%
Tumor Necrosis Factor Inhibitor
8%
Curcumin
7%
Subcutaneous Injection
7%
Prospective Cohort Study
7%
Case-Control Study
6%
mRNA Vaccine
6%
Fibrosis
6%
Vascular Disease
6%
Scalp Psoriasis
6%
Alopecia
6%
Scar Formation
6%
C Reactive Protein
6%
Colitis
5%
